痰热清注射液预防同期放化疗肺癌患者急性放射性肺炎的临床研究

目的 研究痰热清注射液对同期放化疗肺癌患者放射性肺炎的预防及其可能的作用机制.方法 选取扬州大学附属泰兴市人民医院2013年6月至2015年6月期间同期放化疗肺癌患者120例,按随机数表法分为观察组和对照组,每组60例.两组患者均使用医科达加速器行三维适形放疗,靶区剂量控制在56~66 Gy之间,观察组放疗期间同时给予痰热清注射液20 mL静脉滴注,比较治疗结束后两组患者放射性肺炎发生率及放疗前、完成放疗DT 20 Gy、40 Gy、放疗结束时两组患者血清转化生长因子-β1(TGF-β1)和白介素-6(IL-6)水平.结果 观察组患者放射性肺炎及3级以上放射性肺炎发生率分别为18.33%、3.34%,均低于对照组28.33%、6.67%;完成放疗40 Gy及放疗结束时观察组患者血清TGF-β1水平分别为(5.24±2.67)ng/mL、(5.59±2.16)ng/mL,均明显低于对照组的(6.11±2.08)ng/mL、(6.43±2.35)ng/mL,两组比较差异有统计学意义(P<0.05);完成放疗DT 20 Gy、40 Gy及放疗结束时观察组患者的血清IL-6水平分别为(40.15±10.68)ng/L、(43.15±12.59)ng/L、(44.15±11.46)ng/L,均明显低于对照组的(45.06±11.07)ng/L、(50.49±11.73)ng/L、(52.85±13.06)ng/L,两组比较差异有统计学意义(P<0.05).结论 痰热清注射液能够降低同期放化疗肺癌患者放疗后血清TGF-β1和lL-6水平,降低放射性肺炎发病率,提高患者生活质量,对临床有一定指导意义.

Effects of Tanreqing injection for prevention of acute radiation-induced pneumonitis in lung cancer patients receiving concurrent chemoradiotherapy

Objective To study the preventive effect of Tanreqing injection on acute radiation-induced pneumo-nitis in lung cancer patients receiving concurrent chemoradiotherapy. Methods From June 2013 to June 2015, 120 pa-tients with lung cancer in our hospital were randomly divided into control group and observation group, each including 60 patients. All patients received three-dimensional conformal radiation therapy and the total dose was 56~64 Gy. Pa-tients in the observation group were given intravenous infusion of Tanreqing injection (20 mL) during the course of thera-py. The incidences of radiation-induced pneumonia were compared. Transforming growth factorβ1 (TGF-β1) and inter-leukin-6 (IL-6) levels in patients were detected and compared before therapy, at 20 Gy dose, at 40 Gy dose and at the end of therapy. Results After treatment, the incidences of radiation-induced pneumonitis and stageⅢor higher radiation-in-duced pneumonia in the observation group were 18.33% and 3.34%, which were significantly 1ower than 28.33% and 6.67%in the control group. When the patients received 40 Gy dose and finished the therapy, the serum TGF-β1 in observa-tion group were (5.24±2.67) ng/mL, (5.59±2.16) ng/mL, significantly lower than (6.11±2.08) ng/mL, (6.43±2.35) ng/mL in the control group (P<0.05). When the patients received 20 Gy dose, 40 Gy dose and finished the therapy, the serum IL-6 in observation group were (40.15 ± 10.68) ng/L, (43.15 ± 12.59) ng/L, (44.15 ± 11.46) ng/L, significantly lower than (45.06±11.07) ng/L, (50.49±11.73) ng/L, (52.85±13.06) ng/L in the control group (P<0.05). Conclusion Tanreqing in-jection can significantly reduce serum TGF-β1 and IL-6 levels in the lung cancer patients receiving concurrent chemora-diotherapy, reduce the incidence of radiation-induced pneumonitis, and improve the patients'quality of life.